🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

ACADIA Pharmaceuticals Inc. ACAD R2KR3KPHARMA

Healthcare · Biotechnology · United States
https://www.acadia.com
Company Profile ↓
$28.02
+11.50% 1Y
Mkt Cap$4.80B
P/E12.57
P/B3.85
52W High$30.57
52W Low$20.06
Book Value$7.59
EPS (TTM)$2.23

Company Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 35.7%, reflecting efficient use of shareholder capital.

Steady Revenue Expansion

Revenue has grown at a 40.7% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 12.6, below the sector median of 25.2.

Healthy Margins

Maintains a net profit margin of 33.4%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.06.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $1.07B (+11.9% YoY); net profit $391.00M.
  • Trailing 12 Months Year-on-year growth — revenue +16.4%, earnings +13.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 40.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:40.69%
1 Year:16.40%

Compounded Profit Growth

5 Years:-
1 Year:13.30%

Stock Price Performance

1 Year:+11.50%
6 Months:+26.44%
3 Months:+29.96%
1 Month:-1.51%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 76% of range
$20.06 $30.57
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)47.10 · Neutral
Price Performance
1M-1.51%
3M+29.96%
6M+26.44%
1Y+11.50%
Valuation vs Sector

P/E of 12.57 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 35.7%.
  • Excellent profit margin of 33.4%.
  • Compounding revenue at 40.7% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
12.57
Industry PE
25.17
Forward P/E
31.48
PEG Ratio
50.86
Book Value
$7.59
Price to Book
3.85
P/S
4.39
EV/EBITDA
42.18
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
40.69%
Profit 5Y
-
Revenue (YoY)
16.40%
Earnings (YoY)
13.30%

Profitability & Returns

ROCE
8.14%
ROE
35.74%
ROA
3.64%
Profit Margin
33.42%
Op Margin
12.29%
Gross Margin
62.06%
EPS (Latest Qtr)
$0.18
EPS (TTM)
$2.23

Balance Sheet & Liquidity

Debt/Equity
0.06
Quick Ratio
3.11
Current Ratio
3.39
Debt
$73.85M
Total Assets
$1.74B
Current Assets
$1.10B
Working Capital
$785.00M

Ownership

Promoter Holding
0.33%
Chg in Prom Hold
-0.00%
FII / Inst Holding
99.76%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$4.80B
Total Revenue (TTM)
$1.14B
EBITDA
$98.39M
Free Cash Flow
$68.65M
Operating Cash Flow
$160.32M
Shares Outstanding
171.24M
Gross Margin
62.06%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ACAD ACADIA Pharmaceuticals Inc. R2KR3KPHARMA 28.02 12.57 $4.80B 0.00% 8.14% 35.74% 40.69% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ----30.48M35.58M-48.87M57.06M58.30M-62.96M83.20M94.59M-90.07M110.10M120.58M-106.55M115.22M131.61M-115.47M134.56M130.71M-118.46M165.24M211.70M-205.83M241.96M250.40M244.32M264.57M278.63M283.99M268.06M307.96M
Cost of Revenue ----------------------------------20.39M20.73M21.65M26.23M24.79M-
Gross Profit -429.00K4.42M10.26M13.02M28.25M33.44M41.11M46.72M53.50M54.47M56.75M60.01M80.25M92.17M95.31M87.27M107.20M118.57M118.50M104.37M112.69M127.92M128.31M112.52M131.90M128.58M134.08M116.80M157.78M197.08M213.15M---223.93M243.83M256.99M257.76M243.27M-
Operating Expenses ----------------------------------204.63M211.46M221.23M240.37M247.89M-
Operating Income -71.92M-72.40M--88.72M-68.04M-65.64M--54.82M-64.08M-61.27M--87.63M-57.09M-45.42M--89.52M-44.01M-85.90M--66.77M-43.71M-15.30M--113.02M-33.65M-30.87M--53.58M3.04M-57.78M-15.21M30.44M31.64M19.29M32.37M35.76M17.39M-4.62M37.84M
EBITDA ----------------------------------22.24M35.31M38.71M20.32M-1.62M-
Interest Expense ----------------------------------------
Pretax Income ----------------------------------27.78M40.21M44.59M26.32M3.98M-
Tax Provision ----------------------------------8.79M13.54M-27.18M-247.25M344.00K-
Net Income -71.32M-71.61M-78.70M-87.84M-67.44M-65.25M-68.87M-54.30M-63.27M-62.14M-65.49M-85.30M-54.94M-41.98M-53.04M-88.02M-42.14M-84.66M-66.76M-66.45M-43.87M-14.46M-43.09M-113.06M-34.01M-27.18M-41.73M-43.02M1.11M-65.18M45.80M16.55M33.39M32.77M18.99M26.67M71.78M273.57M3.64M31.50M
Diluted EPS --------------------0.42-0.27-0.09-0.27-0.70-0.21-0.17-0.26-0.270.01-0.400.280.100.200.200.110.160.421.600.020.18
R&D Expense 20.48M25.81M-35.41M34.18M36.42M-39.28M46.59M53.11M-52.92M67.32M62.62M-72.64M64.30M120.08M-56.97M56.94M58.56M-128.85M75.65M81.34M-69.14M58.77M156.96M-59.68M76.23M66.61M78.27M77.95M87.83M-76.87M81.56M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 6.40M42.13M2.07M4.91M1.15M120.00K61.00K17.33M124.90M223.81M339.08M441.75M-517.24M726.44M957.80M1.07B
Cost of Revenue -------------10.17M41.64M81.84M89.00M
Gross Profit -------14.25M115.82M211.43M327.73M431.54M-507.07M684.80M875.96M982.51M
Operating Expenses -------------730.66M758.18M791.68M877.70M
Operating Income -45.47M15.09M-22.85M-20.89M-38.30M-93.23M-164.61M-272.81M-292.41M-247.44M-246.54M-286.59M--223.60M-73.38M84.28M104.81M
EBITDA --------------221.57M-67.83M100.16M116.57M
Interest Expense -----------------
Pretax Income --------------213.44M-51.04M258.07M138.90M
Tax Provision -------------2.53M10.25M31.62M-252.10M
Net Income -45.15M15.14M-22.77M-20.85M-37.95M-92.47M-164.44M-271.39M-289.40M-245.19M-235.26M-281.58M--215.97M-61.29M226.45M391.00M
Diluted EPS -1.200.39-0.44-0.38--------1.79--1.34-0.371.362.30
R&D Expense 41.59M20.58M17.31M18.79M26.72M60.60M73.87M99.28M149.19M187.16M240.38M319.13M239.41M361.57M351.62M303.25M328.80M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --38.39M32.11M108.59M189.12M325.46M221.90M561.15M384.51M540.20M783.18M782.62M-587.81M748.96M1.19B1.56B
Current Assets --------------507.94M616.12M938.32M1.06B
Cash & Equivalents 21.17M18.12M6.85M6.89M57.90M11.71M61.85M102.14M163.62M69.42M134.76M189.68M326.03M-114.85M188.66M319.59M177.69M
Inventory --------------6.64M35.82M21.95M34.67M
Receivables --------------62.20M98.27M98.74M121.46M
Total Liabilities --8.71M8.75M5.95M6.99M15.97M22.13M42.74M49.22M61.12M84.05M155.61M-187.40M317.20M454.96M336.81M
Current Liabilities --5.96M6.17M5.95M6.98M15.83M21.90M42.59M49.03M59.56M74.83M105.97M-125.63M254.25M394.87M277.11M
Long Term Debt ------------------
Total Debt --------------62.00M57.20M51.99M52.19M
Total Equity 52.99M12.11M29.69M23.36M84.98M182.13M309.49M199.76M518.41M335.29M479.08M699.13M627.01M-400.41M431.75M732.79M1.23B
Shares Outstanding --------------162.06M164.65M166.71M170.31M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -13.73M-10.70M-19.90M-21.63M----208.41M-217.76M-167.47M-151.13M-136.17M--114.03M16.70M157.72M109.84M
Investing Cash Flow 9.44M-1.06M5.98M-25.53M----261.92M92.47M-71.49M-165.84M192.51M-73.24M32.00M-30.54M-302.56M
Financing Cash Flow 1.16M470.00K13.94M98.17M---533.81M31.19M306.65M371.85M81.00M-8.20M25.13M6.84M49.88M
Capital Expenditure ---3.00K--618.00K-180.00K-2.14M-1.51M-812.00K-2.10M-1.13M-7.59M-1.12M--50.00K-523.00K-4.69M
Free Cash Flow ---19.90M-----209.91M-218.57M-169.57M-152.26M-143.75M--114.03M16.65M157.20M105.15M
Net Change in Cash --------------32.59M73.83M134.03M-142.84M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------82.2%92.7%94.5%96.7%97.7%-98.0%94.3%91.5%91.7%
Operating Margin % -710.5%35.8%-1,105.6%-425.6%-3,344.7%-77,691.7%-269,855.7%-1,574.1%-234.1%-110.6%-72.7%-64.9%--43.2%-10.1%8.8%9.8%
Net Margin % -705.5%35.9%-1,101.4%-424.9%-3,314.2%-77,062.5%-269,578.7%-1,565.9%-231.7%-109.6%-69.4%-63.7%--41.8%-8.4%23.6%36.5%
ROE % -372.7%51.0%-97.4%-24.5%-20.8%-29.9%-82.3%-52.4%-86.3%-51.2%-33.7%-44.9%--53.9%-14.2%30.9%31.9%
ROCE % -46.5%-88.1%-20.3%-21.0%-30.1%-82.3%-52.6%-87.2%-51.5%-34.8%-42.4%--48.4%-14.8%10.6%8.1%

Shareholding Pattern

Insiders
0.33%
Institutions
99.76%
Public Float
100.09%

Top Institutional Holders

#Holder% HeldSharesValue
1 Baker Bros. Advisors, LP 24.91% 42.91M $1.25B
2 Blackrock Inc. 13.07% 22.52M $655.42M
3 State Street Corporation 5.27% 9.08M $264.21M
4 Vanguard Portfolio Management LLC 5.13% 8.84M $257.29M
5 RTW Investments LP 4.15% 7.14M $207.98M
6 Vanguard Capital Management LLC 3.35% 5.76M $167.78M
7 Dimensional Fund Advisors LP 2.14% 3.69M $107.56M
8 Geode Capital Management, LLC 1.95% 3.36M $97.76M
9 Palo Alto Investors Lp 1.66% 2.86M $83.37M
10 Goldman Sachs Group Inc 1.50% 2.58M $75.11M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ACAD

Yahoo Finance hu, 03 Sep 2026

Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo Finance Mon, 24 Aug 2026

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

SAN DIEGO, August 24, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndr…

Yahoo Finance Wed, 12 Aug 2026

Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript

Revenue hit $308 million with 17% growth, driven by DAYBUE and NUPLAZID demand.

Yahoo Finance Mon, 10 Aug 2026

Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says

Acadia Pharmaceuticals (ACAD) could benefit from wider Daybue use, steady Nuplazid growth, higher ca

Yahoo Finance Fri, 07 Aug 2026

Acadia Pharmaceuticals (ACAD) Stock Gets Fair Value Bump As Analysts Back Daybue Growth

ACADIA Pharmaceuticals has seen its fair value price target adjusted from US$31.80 to US$33.25 per share, reflecting updated assumptions around its business outlook. Recent analyst commentary generally sounds constructive, with higher targe…

Yahoo Finance Fri, 07 Aug 2026

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

ACAD — Frequently Asked Questions

What is the current share price of ACADIA Pharmaceuticals Inc. (ACAD)?

As of 2026-09-07 16:24 PDT, ACADIA Pharmaceuticals Inc. (ACAD) trades at $28.02 on NasdaqGS. Its 52-week range is $20.06 to $30.57.

What is the market capitalisation of ACAD?

ACADIA Pharmaceuticals Inc. (ACAD) has a market capitalisation of $4.80B on NasdaqGS.

What is the P/E ratio of ACAD?

ACAD trades at a trailing price-to-earnings (P/E) ratio of 12.57. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.85.

What is the return on equity (ROE) of ACAD?

ACAD has a return on equity (ROE) of 35.74%. Its return on capital employed (ROCE) is 8.14%.

Is ACAD a good stock to buy?

This page provides a data-driven analysis of ACADIA Pharmaceuticals Inc. (ACAD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space